



Gillette India Limited
CIN: L28931MH1984PLC267130
Regd. Office
P&G Plaza, Cardinal Gracias Road,
Chakala, Andheri (E),
Mumbai - 400099
Tel : 91-22-2826 6000
Fax : 91-22-2826 7337
Website: in.pg.com

April 29,2024

To,
The Corporate Relations Department
The BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001
Ref:- Scrip Code:- 507815

To,
The Listing Department
The National Stock Exchange of India Limited
Exchange Plaza, Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (East),
Mumbai - 400051
Ref:- Scrip Code:- GILLETTE

Dear Sir / Madam,

Sub:- Unaudited Financial Results for the quarter ended March 31,2024

We are pleased to inform you that at a meeting of the Board of Directors of the Company held today (commenced at 4:45 pm and ended at 5:35 pm), the Unaudited Financial Results for the quarter ended March 31, 2024 were approved.

We are enclosing herewith the following:

- a. Unaudited Financial Results for the quarter ended March 31, 2024;
- b. Limited Review Report in respect of the Unaudited Financial Results for the quarter ended March 31, 2024 furnished by Statutory Auditors of the Company.

Kindly take the same on record and oblige.

Thanking you,
Yours faithfully,

For Gillette India Limited

Flavia Machado
Company Secretary



Gillette India Limited
 CIN: L28931MH1984PLC267130
 Regd. Office
 P&G Plaza, Cardinal Gracias Road,
 Chakala, Andheri (E),
 Mumbai - 400099
 Tel: (91-22) 2826 6000
 Fax: (91-22) 2826 7337
 Website: in.pg.com

(₹ in Lakhs)						
STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST MARCH 2024						
Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st March 2024	Preceding Three Months Ended 31st December 2023	Corresponding Three Months Ended 31st March 2023	Nine Months Ended 31st March 2024	Corresponding Nine Months Ended 31st March 2023	Previous Year Ended 30th June 2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 Revenue from operations	68 074	63 946	61 907	1 98 775	1 85 761	2 47 705
2 Other income	569	719	1 177	2 152	1 740	2 218
3 Total income (1+2)	68 643	64 665	63 084	2 00 927	1 87 501	2 49 923
4 Expenses						
(a) Cost of raw and packing materials consumed	14 146	19 810	15 099	51 867	54 648	67 849
(b) Purchases of stock-in-trade (Traded goods)	14 560	11 346	12 736	41 389	35 469	49 987
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	3 008	(4 338)	1 248	(4 389)	(3 049)	977
(d) Employee benefits expense	4 538	4 879	5 323	14 756	13 273	16 976
(e) Finance costs	257	325	77	595	461	777
(f) Depreciation and amortization expense	2 064	2 071	2 184	6 144	5 905	8 069
(g) Advertising & sales promotion expenses	6 899	7 577	7 756	24 764	24 741	29 159
(h) Other expenses	8 889	9 091	6 374	25 099	21 127	28 839
Total expenses	54 361	50 761	50 797	1 60 225	1 52 575	2 02 633
5 Profit before tax (3-4)	14 282	13 904	12 287	40 702	34 926	47 290
6 Tax expense						
(a) Current tax	4 091	3 619	3 329	11 216	9 480	12 800
(b) Deferred tax	(368)	(317)	(854)	(944)	(594)	(725)
(c) Prior year tax adjustments	650	207	(458)	857	(353)	(353)
Income tax expense	4 373	3 509	2 017	11 129	8 533	11 722
7 Profit for the period (5-6)	9 909	10 395	10 270	29 573	26 393	35 568
8 Other comprehensive income						
Items that will not be reclassified to profit or loss:						
Re- measurement of the defined benefit plans	299	917	172	1 125	(89)	(364)
Income tax effect on above	(75)	(231)	(44)	(283)	22	92
Total other comprehensive income	224	686	128	842	(67)	(272)
9 Total comprehensive income for the period (7+8)	10 133	11 081	10 398	30 415	26 326	35 296
10 Paid-up equity share capital (Face Value ` 10 per Equity Share)	3 259	3 259	3 259	3 259	3 259	3 259
11 Other Equity						95 627
12 Earnings per share (Face value of ` 10/- per equity share) (not annualised):						
(a) Basic	30.41	31.91	31.52	90.76	81.00	109.15
(b) Diluted	30.41	31.91	31.52	90.76	81.00	109.15

See accompanying notes to the Financial Results

Segment wise Revenue, Results, Assets and Liabilities under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015:

(₹ in Lakhs)

Particulars	(1)	(2)	(3)	(4)	(5)	(6)
	Three Months Ended 31st March 2024	Preceding Three Months Ended 31st December 2023	Corresponding Three Months Ended 31st March 2023	Nine Months Ended 31st March 2024	Corresponding Nine Months Ended 31st March 2023	Previous Year Ended 30th June 2023
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1. Segment Revenue						
- Grooming	55 771	51 421	49 135	1 59 939	1 47 525	1 96 062
- Oral Care	12 303	12 525	12 772	38 836	38 236	51 643
Total Income from Operations	68 074	63 946	61 907	1 98 775	1 85 761	2 47 705
2. Segment Results (Profit/(Loss)) before finance costs and tax						
- Grooming	11 929	12 904	9 145	34 162	28 781	37 774
- Oral Care	2 146	649	1 949	5 357	4 783	7 942
Total Segment Results	14 075	13 553	11 094	39 519	33 564	45 716
Less: Finance costs	(257)	(325)	(77)	(595)	(461)	(777)
Add/(Less): Unallocable Income net of Unallocable Expenditure	464	676	1 270	1 778	1 823	2 351
Total Profit Before Tax	14 282	13 904	12 287	40 702	34 926	47 290
3. Segment assets						
- Grooming	86 484	98 068	1 01 096	86 484	1 01 096	1 03 796
- Oral Care	7 782	9 353	10 073	7 782	10 073	11 064
Total Segment Assets	94 266	1 07 421	1 11 169	94 266	1 11 169	1 14 860
- Unallocated Corporate Assets	69 344	73 699	76 914	69 344	76 914	76 755
Total Assets	1 63 610	1 81 120	1 88 083	1 63 610	1 88 083	1 91 615
4. Segment liabilities						
- Grooming	46 025	46 360	63 754	46 025	63 754	57 015
- Oral Care	11 841	12 826	16 788	11 841	16 788	14 713
Total Segment Liabilities	57 866	59 186	80 542	57 866	80 542	71 728
- Unallocated Corporate Liabilities	20 157	18 869	17 797	20 157	17 797	21 001
Total Liabilities	78 023	78 055	98 339	78 023	98 339	92 729

Notes to Segment:

- Segments have been identified in line with the Indian Accounting Standard (Ind AS) 108- Operating Segments.
- Grooming segment produces and sells shaving system and cartridges, blades, toiletries and components. Oral Care segment produces and sells tooth brushes and oral care products.
- All assets are allocated to reportable segments other than loans, other financial assets and income and deferred tax assets. Assets used jointly by reportable segments are allocated on the basis of the revenues earned by individual reportable segments.
- All liabilities are allocated to reportable segments other than provisions, other current liabilities and current tax liabilities. Liabilities for which reportable segments are jointly liable are allocated in proportion to the segment cost ratio.

Notes :

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on April 29, 2024 and have been subjected to a limited review by the Statutory Auditors of the Company.
- The Company has arrived at an advanced pricing agreement with the concerned tax authorities, determining appropriate transfer pricing methodology for certain identified transactions with the Company's affiliate(s) for the years viz., F.Y. 2012-13, F.Y. 2014-15 to F.Y. 2016-17. As a consequence of this agreement, an additional tax liability amounting to ₹ 650 lakhs and interest of ₹139 lakhs, has been accounted under Prior Period Tax Adjustments and Finance Costs respectively. Further, there will be a reduction in contingent liabilities of approximately ₹25 005 lakhs subject to withdrawal of relevant tax litigations by the respective parties.

For and on behalf of the Board of Directors of
Gillette India Limited

LALGUDI
VISWANATHA
N
VAIDYANATH
Date: 2024.04.29
17:35:18 +05'30'

L. V. Vaidyanathan
Managing Director
DIN: 09632201

Place: Mumbai
Date: April 29, 2024

KALYANIWALLA & MISTRY LLP

CHARTERED ACCOUNTANTS

**REVIEW REPORT
TO THE BOARD OF DIRECTORS
GILLETTE INDIA LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **GILLETTE INDIA LIMITED** (“the Company”) for the quarter and nine months ended March 31, 2024, together with the notes thereon, (“the Statement”) attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, duly initialled by us for identification. This Statement which is the responsibility of the Company’s Management has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on April 29, 2024, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 ‘Interim Financial Reporting’ (‘Ind AS 34’), prescribed under section 133 of the Companies Act, 2013 (“the Act”) read with relevant Rules issued thereunder, as applicable and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KALYANIWALLA & MISTRY LLP
CHARTERED ACCOUNTANTS**

Firm Reg. No.: 104607W / W100166



Daranis Z. Fraser

PARTNER

M. No. 42454

UDIN: 24042454BK BK CO 9554

Mumbai, April 29, 2024.

LLP IN : AAH - 3437

REGISTERED OFFICE : ESPLANADE HOUSE, 29, HAZARIMAL SOMANI MARG, FORT, MUMBAI 400 001
TEL.: (91) (22) 6158 6200, 6158 7200 FAX: (91) (22) 6158 6275